Altamira Therapeutics AG

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech company. We are a spin-off of EPFL, dedicated to develop next-generation metabolic cancer immunotherapies. Our exclusive metabolic reprogramming technology reverses T-cell exhaustion, a major bottleneck in cancer immunotherapies.